南模生物(688265) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of approximately 381.93 million yuan, a year-on-year increase of 4.20%[4] - The net profit attributable to the parent company was approximately 6.56 million yuan, marking a turnaround from a loss in the previous year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately -15.52 million yuan, a year-on-year reduction in loss of 60.72%[4] - Basic earnings per share improved to 0.09 yuan from -0.26 yuan in the previous year[3] - The weighted average return on net assets increased to 0.38% from -1.17%[3] Assets and Equity - Total assets at the end of the reporting period were approximately 1.93 billion yuan, a decrease of 3.45% from the beginning of the period[3] - Equity attributable to the parent company decreased by 3.09% to approximately 1.68 billion yuan[3] Revenue Sources - The company experienced stable growth in revenue from domestic research clients, while industrial revenue slightly declined due to the investment environment in the domestic biopharmaceutical industry[5] - The company actively expanded its overseas market, resulting in a rapid increase in overseas business revenue[5] Non-Recurring Gains - Non-recurring gains such as financial investment income and government subsidies increased year-on-year, contributing to the company's profitability[6]